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Summary
Extensive evidence suggests that the immune system exerts powerful effects
on bone cells, particularly in chronic disease pathologies such as rheumatoid
arthritis (RA). The chronic inflammatory state in RA, particularly the exces-
sive production of T cell-derived proinflammatory cytokines such as tumour
necrosis factor (TNF)-α and interleukin (IL)-17, triggers bone erosions
through the increased stimulation of osteoclast formation and activity.
While evidence supports a role for IL-17 and TNF-α secreted by conven-
tional CD4+ T cells in RA, recent evidence in animal models of RA have
implicated γδ T cells as a major producer of pathogenic IL-17. However, the
capacity of γδ T cells to influence osteoclast formation and activity in
humans has not yet been investigated widely. To address this issue we investi-
gated the effects of γδ T cells on osteoclast differentiation and resorptive
activity. We have demonstrated that anti-CD3/CD28-stimulated γδ T cells or
CD4+ T cells inhibit human osteoclast formation and resorptive activity in
vitro. Furthermore, we assessed cytokine production by CD3/CD28-
stimulated γδ T cells and observed a lack of IL-17 production, with activated
γδ T cells producing abundant interferon (IFN)-γ. The neutralization of
IFN-γ markedly restored the formation of osteoclasts from precursor cells
and the resorptive activity of mature osteoclasts, suggesting that IFN-γ is the
major factor responsible for the inhibitory role of activated γδ T cells on
osteoclastogenesis and resorptive activity of mature osteoclasts. Our work
therefore provides new insights on the interactions between γδ T cells and
osteoclasts in humans.
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Introduction
Bone tissue is constantly remodelled during life through the
activity of bone matrix-producing osteoblasts and bone-
resorbing osteoclasts [1]. Osteoclasts are large multi-
nucleated cells that are generated from the fusion of
monocytic-lineage precursor cells, the process of which
relies on the availability on two essential factors:
macrophage colony-stimulating factor (M-CSF), which
binds the c-Fms receptor expressed on osteoclast precursors
[2], and receptor activator of nuclear factor κB ligand
(RANKL), which binds the RANK receptor [3].
In recent years a variety of studies have demonstrated
that the immune system is involved intimately in the regu-
lation of bone cells, with a particular focus on how T cells
interact with osteoclasts and influence their formation
and/or activity. In chronic inflammatory disease states,
such as rheumatoid arthritis (RA), the prevalent effect of
activated CD4+ T cells is stimulatory towards the formation
and activity of osteoclasts, resulting in bone loss and degra-
dation of joint architecture [4]. However, evidence sur-
rounding the exact role of activated T cells for influencing
osteoclast formation is currently conflicting, with numer-
ous in-vitro studies reporting either pro- or anti-
osteoclastogenic effects of activated CD4+ T cells [5,6].
Activated CD4+ T cells produce RANKL [4] and various
cytokines, including interleukin (IL)-17 [7], tumour necro-
sis factor (TNF)-α [8] and IL-1β [9] that support osteo-
clast formation and activity through direct or indirect
mechanisms. However, CD4+ T cells also produce a variety
bs_bs_banner
Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12165
281© 2013 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 174: 281–291
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
of cytokines with anti-osteoclastogenic effects, such as
interferon (IFN)-γ [6], granulocyte–macrophage colony-
stimulating factor (GM-CSF) [10], IL-4 [11] and IL-10 [12].
While research has focused predominantly on the role of
CD4+ T cells in inflammatory arthritis, a recent study impli-
cated a further subset of T cells, so-called γδ T cells, as
important mediators of the disease pathology in the
collagen-induced arthritis (CIA) model of inflammatory
arthritis [13]. Through production of IL-17, γδ T cells drive
bone loss by increasing the production of RANKL by
osteoblasts and/or stromal cells and inducing sustained
osteoclast formation. In humans, γδ T cells represent a
small subset of T cells (up to 5% of the total peripheral
blood T cells), which express a heterodimeric T cell receptor
(TCR) composed of a particular γ and δ chain, in contrast
to conventional CD4+ T cells that express a heterodimeric
TCR composed of an α and a β chain [14]. In support of a
role of γδ T cells in the disease pathology of human RA, γδ
T cells are present in the inflamed joints of rheumatoid
arthritis patients [15,16], and have been shown to be
capable of producing IL-17 upon activation under extreme
polarizing conditions [17,18]. Furthermore, the activation
of γδ T cells and its potential relevance to human health is
of great clinical interest, particularly as the major subset of
γδ T cells in human peripheral blood (Vγ9Vδ2+) are acti-
vated by anti-resorptive nitrogen–bisphosphonate drugs
(N-BPs) [19,20], which are used widely to treat a variety of
bone diseases characterized by excessive osteoclast activity.
However, currently the role of human γδ T cells for
influencing osteoclast formation and activity has not been
elucidated.
In this study we show that activated γδ T cells exert
inhibitory effects on osteoclast formation and resorptive
activity comparable to activated CD4+ T cells, which is
mediated primarily through production of IFN-γ by acti-
vated γδ T cells. Despite producing a variety of pro-
osteoclastogenic cytokines upon activation, freshly isolated
γδ T cells consistently failed to produce IL-17 ex vivo, sug-
gesting important functional differences between murine
and human γδ T cells for influencing osteoclastogenesis in
inflammatory conditions.
Materials and methods
T cell isolation and activation
Peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats obtained from healthy donors by density-
gradient separation using Lymphoprep™ reagent (Axis-
Shield, Dundee, UK). Buffy coats were provided by the
Scottish National Blood Transfusion Service and all studies
were approved by the North of Scotland Research Ethics
Committee. γδ T cells and CD4+ T cells were positively iso-
lated using magnetic-activated cell sorting (MACS®)
(Miltenyi Biotec, Bergisch Gladbach, Germany) using anti-
γδ-TCR and anti-CD4-TCR beads, respectively. To increase
the purity of γδ and CD4+ T cell isolations, CD14+ cells were
depleted prior to T cell isolation, using anti-CD14+
Dynabeads® (Invitrogen, Carlsbad, CA, USA). The purity of
the isolated T cell subsets was assessed by flow cytometry,
with routine purities of ≥95% obtained for γδ T cells and
>98% for CD4+ T cells. Assessment of monocyte and B cell
contamination in the γδ T cell cultures was investigated
using anti-CD14-Pacific Orange (Invitrogen) and anti-
CD19-phycoerythrin (PE)-CF594 (BD Biosciences, San
Jose, CA, USA) antibodies, respectively, and was found rou-
tinely to be approximately 1% for both monocytes and B
cells. γδ and CD4+ T cells were activated with anti-CD3/
anti-CD28-coated T-Activator Dynabeads® (Invitrogen) at
a bead-to-cell ratio of 1:1 for 24 h, prior to incubation with
autologous osteoclast precursors or mature osteoclasts.
Activation of T cells was assessed using an anti-human
CD69-PE antibody (BD Biosciences) and subsequent flow
cytometric analysis using a LSR II flow cytometer (BD
Biosciences).
Isolation of osteoclast precursors and generation of
mature osteoclasts
Osteoclast precursors were isolated from buffy coats from
healthy donors using Lymphoprep™ density-gradient sepa-
ration and cultured in α-minimum essential medium
(Sigma, St Louis, MO, USA) supplemented with 100 μg/ml
L-glutamine (Sigma), 100 U/ml penicillin/streptomycin
(Sigma) and 10% (v/v) heat-inactivated fetal bovine serum
(FBS). Osteoclast precursors were expanded prior to gen-
eration of osteoclasts as reported previously [21]. Briefly,
osteoclast precursors were treated with 20 ng/ml recombi-
nant human (rh)M-CSF (R&D Systems, Abingdon, UK) for
5–7 days. To stimulate osteoclast formation, osteoclast pre-
cursors were cultured in a 96-well plate at 2 × 104 cells/well
and treated with 2 ng/ml recombinant mouse (rm)RANKL
(R&D Systems) for 5–6 days in the presence of 5 × 104
autologous unstimulated or activated γδ T cells or CD4+ T
cells. Cells were subject to half-medium changes and sup-
plemented with fresh cytokines every 48 h. In some experi-
ments osteoclast precursor cells were incubated with
10% (v/v) conditioned media from γδ or CD4+ T cells
stimulated for 24 h with anti-CD3/anti-CD28-coated
T-Activator Dynabeads® (Invitrogen) and 10 U/ml of IL-2
(Sigma-Aldrich, Gillingham, UK).
For cytokine neutralization studies, the following
antibodies were used: affinity-purified polyclonal goat anti-
human IFN-γ antibody (10 μg/ml; R&D Systems), anti-
human GM-CSF (1 μg/ml) and rat IgG2a isotype control
(1 μg/ml) (both eBioscience, Vienna, Austria).
Osteoclast resorptive activity
Mature osteoclasts were generated on plastic for 5 days in
the presence of 20 ng/ml rhM-CSF and 2 ng/ml rmRANKL,
A. Pappalardo & K. Thompson
282 © 2013 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 174: 281–291
as reported previously [21]. Following this period, differen-
tiated osteoclasts were detached with trypsin and plated
onto dentine discs (obtained from elephant ivory) in a
96-well plate, at a density of 2 × 104 cells/well. Following a
period of attachment (4 h), osteoclasts were co-cultured for
5 days with 5 × 104 autologous activated γδ T cells or CD4+
T cells in the presence of 20 ng/ml rhM-CSF and 2 ng/ml
rmRANKL. In some experiments mature osteoclasts were
cultured in the presence of 10% (v/v) conditioned media
from γδ or CD4+ T cells generated as described above. Cul-
tures were subject to half-medium changes with fresh
cytokines and conditioned medium added every 48 h. To
assess osteoclast resorptive activity, images of the dentine
discs were captured using reflected light microscopy and the
total resorbed surface area of dentine was quantified using
in-house software to establish a grey threshold to determine
the area resorbed by osteoclasts (in black) and non-
resorbed surfaces (in white).
Immunohistochemistry
Osteoclast formation was assessed using immunohisto-
chemical staining for expression of the vitronectin receptor
(VNR) by mature osteoclasts using a mouse anti-CD51/
CD61 antibody (AbD Serotec, Oxford, UK) and goat anti-
mouse Alexa Fluor®-488 antibody (Molecular Probes,
Carlsbad, CA, USA). Osteoclast formation was quantified
by assessing multi-nucleated (≥3 nuclei) osteoclast number
using fluorescence microscopy after nuclear counter-
staining with 4′,6-diamidino-2-phenylindole (DAPI).
To visualize polarized osteoclasts on dentine, the
osteoclasts were fixed with 4% formaldehyde, prior to
immunohistochemical staining for F-actin rings using
tetramethylrhodamineisothiocyanate (TRITC)-phalloidin
(Sigma-Aldrich) and quantification using fluorescence
microscopy.
Cytokine production
Conditioned medium generated from activated γδ T cells
and CD4+ T cells was assessed for levels of IL-4, IL-10,
IFN-γ, TNF-α, IL-6 and IL-1β using a cytometric bead
array (BD Biosciences) and analysed using a fluorescence
activated cell sorter (FACS)Array flow cytometer. Produc-
tion of IL-17 was determined using a R&D Systems
Quantikine enzyme-linked immunosorbent assay (ELISA)
kit, according to the manufacturer’s instructions. Produc-
tion of GM-CSF was assessed using a Milliplex Bead Assay
(Millipore, Billerica, MA, USA) and a Bio-Plex 200 analyser
(Bio-Rad, Hercules, CA, USA).
Statistical analysis
Data were analysed using the Kruskal–Wallis one-way
analysis of variance on ranks (SigmaPlot®11·0), with inter-
group comparisons analysed using the Wilcoxon matched-
pairs rank test. P-values ≤0·05 were considered statistically
significant.
Results
Activated γδ T cells inhibit osteoclast formation
To determine the effects of γδ T cells on osteoclast forma-
tion, purified γδ T cells (unstimulated or activated with
anti-CD3/anti-CD28-coated Dynabeads®) were cultured
with autologous M-CSF-dependent osteoclast precursors
for 6 days in the presence of M-CSF and RANKL. Because
VNR is also expressed on activated macrophages [22], we
used multi-nuclearity (≥3 nuclei) in combination with VNR
positivity as a determinant of osteoclast formation in our
assays, as reported previously [23]. Co-cultures of osteoclast
precursors and T cells were supplemented with exogenous
RANKL as activated γδ or CD4+ T cells consistently failed to
induce osteoclast formation in the absence of RANKL in
our in-vitro assay system (data not shown). Osteoclast pre-
cursors were cultured with M-CSF alone to assess basal
levels of spontaneous osteoclast formation.
The presence of unstimulated γδ T cells resulted in a
non-statistically significant trend towards an increased
number of VNR+ osteoclasts compared to RANKL + M-CSF
alone, suggesting a potential stimulatory effect of
unstimulated γδ T cells on osteoclast formation (Fig. 1a),
whereas unstimulated CD4+ T cells had no stimulatory
effect on osteoclast formation. Conversely, the addition of
anti-CD3/CD28 stimulated γδ T cells or CD4+ T cells
(Fig. 1b) resulted consistently in a significant inhibition of
multi-nucleated VNR+ osteoclast formation (Fig. 1a). The
marked inhibitory effect of activated T cells (both γδ and
CD4+) on osteoclast formation was found to be independ-
ent of cell–cell contact, as the addition of 10% (v/v) condi-
tioned medium from activated γδ T cells (Fig. 2a,c) or CD4+
T cells (Fig. 2b,c) was sufficient to markedly inhibit osteo-
clast formation. Furthermore, using Transwell inserts to
isolate activated T cells from osteoclast precursors, we
observed no decrease in the capacity of activated γδ T cells
or CD4+ T cells for inhibiting osteoclast formation (Fig. S1).
Cytokine production by activated γδ T cells and
activated CD4+ T cells
To identify potential mediators of the inhibitory effects of T
cells on osteoclast formation we assessed the levels of bone-
active cytokines produced by unstimulated γδ and CD4+ T
cells and following 24 h stimulation with anti-CD3/anti-
CD28-coated Dynabeads (Table 1).
Following activation, γδ T cells and CD4+ T cells were
found to produce significant levels of IFN-γ, IL-10, TNF-α,
IL-1β, IL-6 and GM-CSF compared to unstimulated cells.
GM-CSF production was not detected in unstimulated
γδ T cells and osteoclasts
283© 2013 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 174: 281–291
CD4+ T cells, but was increased markedly following activa-
tion, with levels increased markedly (∼20-fold) compared
to activated γδ T cells. While IL-4 production was not
increased significantly in γδ T cells, CD4+ T cells increased
IL-4 production significantly following activation. The
marked production of IFN-γ, IL-4, IL-17 and IL-10 by acti-
vated CD4+ T cells reflects the heterogeneous nature of cells
in this population, i.e. T helper type 1 (Th1), Th2, Th17 and
regulatory T cells (Treg). Interestingly, we observed marked
production of IL-17 in activated CD4+ T cells, but not acti-
vated γδ T cells, suggesting that γδ T cells isolated from
healthy volunteers do not produce IL-17 ex vivo following
anti-CD3/CD28 stimulation. Of further note, unstimulated
γδ T cells produced increased levels of IL-6 (∼10-fold
higher) compared to unstimulated CD4+ T cells, which may
explain the tendency of unstimulated γδ T cells to enhance
RANKL-induced osteoclastogenesis (Fig. 1a). This is con-
sistent with a previous study documenting the heterogene-
ity of γδ T cells for producing IL-6 in healthy donors [24].
IFN-γ is the primary mediator of the
anti-osteoclastogenic effect of activated γδ T cells
Following the observation that high levels of IFN-γ are pro-
duced by activated γδ and CD4+ T cells and this is reported
to inhibit osteoclastogenesis [6], we sought to determine if
neutralization of IFN-γ could prevent the inhibitory effects
of activated T cell conditioned medium. The addition of an
anti-IFN-γ antibody restored osteoclast formation signifi-
cantly in the presence of activated γδ T cell conditioned
medium (Fig. 2a,c), suggesting that the soluble factor
responsible for the inhibitory effects of activated γδ T cell
conditioned medium on osteoclastogenesis is IFN-γ. Anti-
IFN-γ treatment only partially overcame the inhibitory
effects of activated CD4+ T cell conditioned medium on
osteoclastogenesis (Fig. 2b,c) suggesting that, while IFN-γ
mediated some inhibitory effects of activated CD4+ T cells,
there are further inhibitory factors produced by CD4+ T
cells that potently inhibit osteoclastogenesis.
A further potential mechanism through which activated
T cells may inhibit osteoclast formation is through produc-
tion of GM-CSF which, in the presence of RANKL, induces
osteoclast precursors to differentiate down the dendritic cell
lineage [10]. However, the neutralization of GM-CSF did
not overcome the inhibitory effects of conditioned medium
from activated γδ T cells (Fig. S2a) or CD4+ T cells
(Fig. S2b) on osteoclast formation. This suggests that IFN-γ
is the primary mediator of the inhibitory effects of activated
γδ T cells on osteoclastogenesis, while diversion of osteo-
clast precursor differentiation towards the dendritic cell
lineage by GM-CSF had no effect in our in-vitro assay
system.
Given the powerful inhibitory effects of γδ T cells stimu-
lated with anti-CD3/CD28 beads for affecting osteoclast
formation, we then sought to determine whether γδ T cells
activated with N-BPs [such as zoledronic acid (ZOL)] had
similar inhibitory effects on osteoclast formation. ZOL-
expanded Vγ9Vδ2 T cells consistently inhibited RANKL-
induced osteoclast formation, and even more pronounced
effects on osteoclast formation were observed following the
addition of 10% (v/v) conditioned medium obtained from
these expanded cultures (Fig. S3). The inhibitory effects of
ZOL-activated Vγ9Vδ2 T cells (or conditioned medium
from these cultures) on osteoclast formation could be
markedly prevented following neutralization of IFN-γ, indi-
cating that IFN-γ is also the major soluble factor responsible
300(a)
M
ul
tin
uc
le
at
ed
 V
NR
+
 
ce
lls
/w
el
l
(%
 of
 co
ntr
ol)
250
200
150
100
50
*
*
*
*
*
*
*
0
RANKL
M-CSF
anti-CD3/CD28
(b)
CD69 CD69
Resting
Activated
+
+
+
+
+
+
+
+
−
+
+
−
+
+
−
−
+
−
CD4
CD4+ T cells
γδ
γδ T cells
Fig. 1. Activated γδ T cells and CD4+ T cells inhibit osteoclast
formation. (a) Quantification of osteoclast formation following
incubation of osteoclast precursor cells with resting or activated
γδ or CD4+ T cells. Macrophage colony-stimulating factor
(M-CSF)-dependent osteoclast precursors were cultured in the
presence of M-CSF and receptor activator of nuclear factor κB-ligand
(RANKL) and co-cultured with resting or anti-CD3/CD28-stimulated
γδ T cells or CD4+ T cells, for 5 days. Osteoclast formation was
assessed using immunohistochemical staining for vitronectin receptor
(VNR) and counterstaining with 4′,6-diamidino-2-phenylindole
(DAPI). Multi-nucleated (≥3 nuclei) VNR+ cells per well were
quantified using fluorescence microscopy. Data shown are the
mean ± standard error of the mean from three experiments from
independent donors. *P < 0·05. (b) Activation of γδ T cells and CD4+
T cells following activation with anti-CD3/CD28 T activator beads.
Purified T cells were stimulated with anti-CD3/CD28 beads (1:1 ratio)
for 24 h, prior to staining with anti-human CD69-phycoerythrin (PE)
antibody and flow cytometric analysis. Data shown are from one
experiment and are representative of two further experiments from
independent donors.
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for the inhibitory effects of ZOL-activated Vγ9Vδ2 T cells
on osteoclast formation.
Activated γδ T cells inhibit osteoclast resorptive activity
To assess whether activated γδ T cells can influence osteo-
clast resorption, we seeded mature osteoclasts onto dentine
discs, co-cultured them with γδ T cells or CD4+ T cells for 6
days and assessed resorptive capacity. Both activated γδ
(Fig. S4a) and CD4+ T cells (Fig. S4b) reduced the osteoclast
resorption area significantly by ∼60 and 70%, respectively.
To assess whether the observed inhibitory effects of acti-
vated T cells were again due to the release of soluble inhibi-
tors we conducted similar experiments using activated T
cell-derived conditioned medium. In the presence of either
activated γδ T cell or CD4+ T cell conditioned medium we
observed markedly reduced resorptive activity compared to
control osteoclasts (Fig. 3a,b).
Due to the powerful inhibitory role of γδ T cell-derived
IFN-γ on osteoclastogenesis we assessed whether IFN-γ was
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Fig. 2. The blockade of interferon (IFN)-γ
partially overcomes the inhibitory effect of
activated γδ T cells, but not CD4+ T cells.
Macrophage colony-stimulating factor
(M-CSF)-dependent osteoclast precursors were
cultured in the presence of receptor activator of
nuclear factor κB-ligand (RANKL) and
co-cultured with 10% (v/v) conditioned
medium (CM) from activated γδ T cells (a) or
10% (v/v) CM from activated CD4+ T cells (b),
in the presence or absence of α-IFN-γ.
Following immunohistochemical staining for
vitronectin receptor (VNR), cells were
counterstained with DAPI and multinucleated
(≥3 nuclei) VNR+ cells per well were quantified
using fluorescence microscopy. Data shown are
the mean ± standard error of the mean from
three experiments from independent donors.
*P < 0·05; ***P < 0·001. (c) Representative
images showing anti-VNR staining (green) and
nuclei (blue) of osteoclast precursor cells
treated with M-CSF and RANKL (i), and higher
magnification view in (iv); 10% (v/v) CM from
activated γδ T cells alone (ii) or in the presence
of α-IFN-γ (iii); 10% (v/v) CM from activated
CD4+ T cells alone (v) or in the presence of
α-IFN-γ (vi). Scale bars are 50 μM (i–iii; v–vi)
and 20 μM (iv).
Table 1. Cytokine production from activated γδ and CD4+ T cells.
Cytokine concentration (pg/ml)
P n
Cytokine concentration (pg/ml)
P nResting γδ Activated γδ Resting CD4 Activated CD4
IFN-γ 21·8 ± 8·0 1124·6 ± 513·3 <0·001 10 3·0 ± 2·2 1605·1 ± 423·9 <0·001 8
IL-4 3·8 ± 1·6 10·0 ± 2·6 n.s. 8 3·0 ± 1·8 107·6 ± 37·9 <0·001 8
IL-10 5·5 ± 0·9 30·7 ± 8·1 <0·05 9 2·5 ± 1·3 630·5 ± 173·9 <0·001 8
TNF-α 33·4 ± 8·5 1050·4 ± 256·9 <0·001 10 4·4 ± 2·1 2630·1 ± 440·4 <0·001 8
IL-1β 12·6 ± 2·8 54·9 ± 11·9 <0·05 6 2·4 ± 0·8 68·4 ± 21·8 <0·05 6
IL-6 151·7 ± 33·3 430·1 ± 131·1 <0·05 10 14·2 ± 4·4 327·6 ± 94·3 <0·05 8
IL-17 4·3 ± 4·2 13·5 ± 10·9 n.s. 16 9·7 ± 9·7 354·6 ± 118·5 <0·001 14
GM-CSF 0·7 ± 0·4 209·1 ± 60·9 <0·05 3 n.d. 4412·5 ± 1575·9 – 3
The production of pro- and anti-osteoclastogenic cytokines was determined for resting γδ and CD4+ T cells, and following anti-CD3/anti-CD28
stimulation for 24 h. Production of interferon (IFN)-γ, interleukin (IL)-10, tumour necrosis factor (TNF)-α, IL-1β, IL-6 and granulocyte–
macrophage colony-stimulating factor (GM-CSF) was assessed using a multiplexed cytometric bead array. IL-17 production was assessed by enzyme-
linked immunosorbent assay (ELISA). Data shown are mean ± standard error of the mean from independent experiments from n number of inde-
pendent donors (n.s. = not significant; n.d. = not determined).
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responsible for the inhibitory effects on osteoclast resorp-
tion. Neutralization of IFN-γ resulted in the almost com-
plete restoration of the resorption area in osteoclasts treated
with activated γδ T cell conditioned medium and markedly
overcame the inhibitory effects of CD4+ T cell conditioned
medium (Fig. 3a,b), suggesting that IFN-γ is the predomi-
nant soluble factor responsible for the inhibitory effect of
both activated γδ and CD4+ T cell conditioned medium on
resorption of mature osteoclasts. The marked inhibitory
effect on osteoclast resorption was paralleled by a profound
reduction in F-actin ring number in cultures treated with
either activated γδ T cell conditioned medium or activated
CD4+ T cell conditioned medium (Fig. 4a,b), which was
comparable in efficacy to rhIFN-γ treatment, and thereby
demonstrates the importance of F-actin ring formation for
osteoclastic resorptive activity. In agreement with the quan-
tified resorption data, this inhibitory effect of γδ T cell con-
ditioned medium on F-actin ring number was completely
abolished when IFN-γ was neutralized (Fig. 4a,b).
Discussion
Numerous studies have reported that activated T cells are
capable of influencing osteoclastogenesis either positively or
negatively, with a recent focus on the stimulatory nature of
the IL-17-producing Th17 subset of CD4+ T cells on the
pathological bone loss associated with chronic inflamma-
tory disease states [7,25]. IL-17 stimulates RANKL expres-
sion by osteoblasts and stromal cells indirectly, thereby
increasing osteoclastogenesis, and thus Th17 cells may play
a pathological role in bone loss associated with chronic
inflammatory disease states, such as RA. However, in the
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Fig. 3. Activated γδ T cells and CD4+ T cells
inhibit the resorptive activity of mature
osteoclasts. (a) Mature osteoclasts were seeded
onto dentine discs and cultured with 10% (v/v)
activated γδ T cell conditioned medium (CM)
or activated CD4+ T cell CM, in the presence or
absence of α-interferon (IFN)-γ, for 6 days.
100 U/ml recombinant human (rh)-IFN-γ
(R&D Systems) was used as a positive control.
Resorptive area was quantified using reflected
light microscopy and in-house software. Data
shown are the mean ± standard error of the
mean from three experiments from
independent donors. *P < 0·05. (b)
Representative images showing osteoclast
resorption pits on dentine discs: receptor
activator of nuclear factor κB-ligand (RANKL)
and M-CSF alone (i); rhIFN-γ (ii); 10% (v/v)
CM from activated γδ T cells alone (iii), or in
the presence of α-IFN-γ (iv); 10% (v/v) CM
from activated CD4+ T cells alone (v), or in the
presence of α-IFN-γ (vi).
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murine model of human RA, collagen-induced arthritis
(CIA), γδ T cells were identified as a major cell type respon-
sible for IL-17 production [13]. As yet, the contribution of
γδ T cells to chronic autoimmune conditions in humans,
particularly their capacity to influence osteoclastogenesis, is
unknown.
In this study, we identified that activated γδ T cells inhibit
the formation of mature osteoclasts from monocytic lineage
precursors via a cell-contact independent mechanism. γδ T
cells were found to increase production of a variety
of bone-active cytokines with both pro- and anti-
osteoclastogenic effects following anti-CD3/CD28 stimula-
tion, but failed consistently to produce IL-17. This was in
marked contrast to CD4+ T cells, which produced abundant
IL-17 upon activation. Using neutralizing antibodies we
determined that the inhibitory effect of activated γδ T cells
on osteoclastogenesis was mediated predominantly via
IFN-γ, while IFN-γ played a relatively minor role in the
inhibitory effect of activated CD4+ T cells. Finally, we iden-
tified that activated γδ and CD4+ T cells inhibit the
resorptive activity of mature osteoclasts, which is mediated
predominantly by production of IFN-γ.
To date, the effect of T cells on osteoclast formation has
focused predominantly on conventional T cell subsets, such
as CD4+ T cells, while the effects of non-conventional T cell
subsets, such as γδ T cells, for influencing osteoclastogenesis
are currently ill-defined, particularly in humans. We have
found that activation of γδ T cells with anti-CD3/CD28
stimulation results in potent inhibitory effects on
osteoclastogenesis, with similar inhibitory effects observed
with activated CD4+ T cells. The inhibitory effects of acti-
vated CD4+ T cells on osteoclastogenesis are consistent with
previous studies [6,26], and highlight further the funda-
mental importance of route of T cell activation for influ-
encing osteoclastogenesis. Using murine cells, Wyzga et al.
demonstrated that the influence of activated CD4+ T cells
on osteoclastogenesis was crucially dependent upon the
mechanism of activation, with anti-CD3 stimulation result-
ing in an inhibitory effect on osteoclastogenesis, whereas
concanavalin A or phytohaemagglutinin treatment resulted
in stimulatory effects. Thus, it is likely that the numerous
conflicting studies documenting both stimulatory [5]
and inhibitory effects [6] of activated T cells on
osteoclastogenesis reflect the use of a variety of stimulation
protocols, as well as the utilization of both murine and
human assay systems.
By analysing cytokine production in both unstimulated
and anti-CD3/CD28 activated γδ T cells and CD4+ T cells
we observed that, unlike their murine counterparts, purified
human γδ T cells failed consistently to produce detectable
IL-17 ex vivo following stimulation but produced abundant
levels of IFN-γ, thereby displaying a marked Th1 bias, as
reported previously [27]. IL-17 production has been
reported recently in the predominant subset of γδ T cells in
human peripheral blood, Vγ9Vδ2 T cells (also referred to as
Vγ2Vδ2), although typically only <1% of cells from healthy
donors demonstrated IL-17 production following non-
specific activation with phorbol myristate acetate (PMA)
plus ionomycin [17]. Therefore, although it is apparent that
Vγ9Vδ2 T cells can acquire the ability to produce IL-17
following culture with a variety of Th17 differentiation-
promoting cytokines [such as IL-1β, IL-6, IL-23 and trans-
forming growth factor (TGF-β)] [18], it is evident that
freshly isolated human γδ T cells from healthy donors
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Fig. 4. F-actin ring formation in osteoclasts is disrupted by interferon
(IFN)-γ derived from activated γδ T cells. Mature osteoclasts were
seeded onto dentine discs, supplemented with receptor activator of
nuclear factor κB-ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF), and treated with 10% (v/v) conditioned
medium (CM) from activated γδ or CD4+ T cells, in the presence or
absence of α-IFN-γ, for 6 days. (a) F-actin ring number was quantified
by fluorescence microscopy following immunohistochemical staining
using tetramethylrhodamineisothiocyanate (TRITC)-phalloidin. Data
shown are the mean ± standard error of the mean from three
experiments from independent donors. *P < 0·05; **P < 0·05;
***P < 0·001). (b) Representative images of osteoclasts (left panels)
treated with CM from activated γδ (middle panels) or CD4+ T cells
(right panels), in the presence or absence of α-interferon (IFN)-γ.
Asterisks indicate the F-actin rings. Images are from one experiment
and are representative of two further experiments from independent
donors. Scale bar = 50 μM.
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produce IFN-γ preferentially, with potential IL-17 release
probably influenced by the method of stimulation and
culture conditions. Thus, it is possible that in the local
microenvironment of inflamed joints the abundance of
proinflammatory cytokines, coupled with the liberation of
TGF-β from bone matrix due to excessive osteoclast activ-
ity, may provide a suitable environment for the generation
of IL-17-producing γδ T cells.
In support of a pathological role for γδ T cells in human
autoimmune disease, γδ T cells have been reported in the
synovial fluid of RA patients [15,16,28], and an increased
prevalence of IL-17-producing γδ T cells have been detected
very recently in the peripheral blood of patients with
ankylosing spondylitis [28]. Consistent with our findings,
Kenna et al. demonstrated that anti-CD3/CD28 stimulation
of γδ T cells resulted in abundant IFN-γ production in the
absence of increased IL-17 production in healthy controls,
yet in ankylosing spondylitis patients the pattern was
reversed, with a profound reduction in IFN-γ release and a
marked increase in IL-17 production, which was potenti-
ated by IL-23 treatment [29]. However, recent studies in RA
patients have suggested that IL-17 production is due exclu-
sively to CD4+ Th17 cells [30], with no IL-17-producing γδ
T cells resident in synovial fluid or infiltrating the rheuma-
toid synovium [31]. Therefore, despite compelling evidence
for a pathological IL-17-producing role of γδ T cells in
murine experimental arthritis, to date the evidence for a
pathological role of γδ T cells in stimulating bone loss asso-
ciated with chronic inflammatory diseases is currently
lacking. Further studies are therefore warranted to deter-
mine the contribution of γδ T cell-derived IL-17 to chronic
human autoimmune diseases.
During this study IFN-γ was revealed as the major
mediator of the inhibitory effects of activated γδ T cells on
osteoclast formation and resorption. By stimulating the
degradation of the TNF receptor-associated factor 6
(TRAF-6) protein through activation of the ubiquitin–
proteasome system, IFN-γ potently inhibits RANK signal-
ling required for osteoclast formation [6]. Further
inhibitory effects of IFN-γ on osteoclast formation have also
been postulated, including stimulation of apoptosis through
Fas/FasL interactions [32] and decreased expression of
RANKL and c-Fms [33]. Interestingly, despite producing
similar levels of IFN-γ as activated γδ T cells, neutralization
of IFN-γ in activated CD4+ T cell cultures had only a partial
effect on recovering osteoclastogenesis, suggesting that
activated CD4+ T cells are able to suppress osteoclastoge-
nesis via multiple mechanisms, such as through produc-
tion of the well-characterized inhibitors IL-4 [34], and/or
IL-10 [35].
The net contribution of IFN-γ to bone metabolism in
vivo is currently an area of intensive debate, with conflicting
reports documenting both pro- and anti-osteoclastogenic
effects of IFN-γ. The anti-osteoclastogenic effects of IFN-γ
in vivo are supported by the finding that IFN-γ−/− mice expe-
rience enhanced bone resorption during collagen-induced
arthritis [36]. Conversely, a number of studies have
reported pro-osteoclastogenic effects of IFN-γ, as IFN-γ is
an effective treatment for osteopetrosis in humans [37], and
IFN-γ−/− mice are protected from ovariectomy-induced
bone loss [38]. These data suggest that IFN-γ has multiple
roles in pathological bone diseases and further supports the
notion that there exists a complex interplay between the
immune system and regulation of bone homeostasis, par-
ticularly in pathological inflammatory disease states.
The profound inhibitory effect of IFN-γ derived from
activated γδ and CD4+ T cells on resorption by mature
osteoclasts is supported by a previous study showing that
IFN-γ decreases expression of the secreted protease cathep-
sin K in RANKL-treated RAW 264·7 cells (a murine pre-
osteoclastic cell line) [39]. As cathepsin K plays an
important role in the degradation of bone matrix proteins
during bone resorption, this provides a direct link by which
T cell-derived IFN-γ may directly impair resorption by
mature osteoclasts. The inhibitory effects on resorption may
be due partially to an inhibition of further osteoclast forma-
tion during the culture period, rather than direct inhibition
of osteoclast resorptive function per se. However, the pro-
found inhibitory effect of rhIFN-γ on resorption observed
in our assays is strongly indicative of a direct effect of IFN-γ
on resorptive activity by mature osteoclasts, rather than an
inhibitory effect on further osteoclast formation in our
assay system. Furthermore, the importance of IFN-γ to the
efficacy of CD4+ T cells for inhibiting resorption was in
marked contrast to its relative lack of effect for inhibiting
osteoclastogenesis. Taken together, this suggests that IFN-γ
is specifically inhibiting osteoclast resorptive function via
a direct effect on the resorptive capacity of mature
osteoclasts.
The importance of γδ T cells for influencing bone
biology is currently poorly understood, but may be of spe-
cific interest in the context of therapeutic administration of
anti-resorptive aminobisphosphonates drugs (N-BPs). We
and others have shown previously that N-BPs, such as
ZOL, potently induce an IFN-γ-producing phenotype in
γδ T cells in vitro [20] and in vivo [40,41]. By inducing
the accumulation of the γδ-TCR agonists isopentenyl
pyrophosphate (IPP) and dimethylallyl diphosphate
(DMAPP) [42] in monocytic-lineage cells [43], N-BPs
selectively activate the major subset of γδ T cells in periph-
eral blood, so-called Vγ9Vδ2 T cells [19]. Thus N-BPs, by
virtue of their high bone affinity and relatively selective tar-
geting of osteoclasts, potentially induce an IFN-γ-effector
phenotype in Vγ9Vδ2 T cells specifically in the local bone
microenvironment, which may be of relevance in vivo given
the inhibitory effects of ZOL-induced IFN-γ production by
Vγ9Vδ2 T cells on osteoclast formation that we observed in
this study. Such a mechanism may further potentiate the
anti-resorptive effects of N-BPs by inhibiting osteoclast for-
mation and resorption through the direct effects of γδ T
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cell-derived IFN-γ. This further highlights the important
links between the immune system and bone resorbing cells
such as osteoclasts, and suggests that pharmacological
manipulation of innate immune cells, for example with
N-BPs, may have important consequences for host immu-
nity and bone health.
In conclusion, this study demonstrates that activated
human γδ T cells are capable of potent inhibitory effects on
osteoclast formation, and the resorptive activity of mature
osteoclasts, mediated via production of IFN-γ.
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Fig. S1. The inhibitory effect of activated γδ T cells and
CD4+ T cells on osteoclast formation is independent of cell–
cell contact. Quantification of osteoclast formation follow-
ing incubation of osteoclast precursor cells with anti-CD3/
CD28-activated γδ or CD4+ T cells for 5 days, in the
presence of macrophage colony-stimulating factor (M-CSF)
and receptor activator of nuclear factor κB-ligand
(RANKL). Activated γδ T cells and activated CD4+ T cells
were co-cultured with osteoclast precursor cells to permit
cell contact, or cells were separated using a Transwell insert
into which the activated T cells were placed. Osteoclast for-
mation was assessed using immunohistochemical staining
for vitronectin receptor (VNR) and counterstaining with
4′,6-diamidino-2-phenylindole (DAPI). Multi-nucleated
(≥3 nuclei) VNR+ cells per well were quantified using fluo-
rescence microscopy. Data shown are the mean ± standard
deviation from two experiments from independent donors.
Fig. S2. The blockade of granulocyte–macrophage colony-
stimulating factor (GM-CSF) does not overcome the inhibi-
tory effect of activated γδ T cells or CD4+ T cells on
osteoclastogenesis. Osteoclast precursors were cultured in
the presence of receptor activator of nuclear factor
κB-ligand (RANKL) + macrophage colony-stimulating
factor (M-CSF) and treated with 10% (v/v) conditioned
medium (CM) from activated γδ T cells (a), or 10% (v/v)
CM from activated CD4+ T cells (b), in the presence or
absence of αGM-CSF or isotype control [immunoglo-
bulin (Ig)G1], for 5–6 days. Following immunohisto-
chemical staining for vitronectin receptor (VNR)
and nuclear counterstaining with 4′,6-diamidino-2-
phenylindole (DAPI), multi-nucleated (≥3 nuclei) VNR+
cells per well were quantified using fluorescence micros-
copy. Data shown are the mean ± standard error of the
mean from three experiments from independent donors.
*P < 0·05; ***P < 0·001.
Fig. S3. Zoledronate-activated γδ T cells inhibit osteoclast
differentiation via interferon (IFN)-γ. Peripheral blood
mononuclear cells (PBMCs) were seeded in a 24-well plate
at a density of 1 × 106 cells/ml (1 ml/well) in α-minimum
essential medium (MEM) supplemented with 1 μM
zoledronic acid (ZOL) plus 10 U/ml interleukin (IL)-2 and
were cultured for 7 days. Cells were subjected to half-
medium changes every 3 days. After 7 days γδ T cells were
positively isolated using γδ T cell magnetic affinity cell
sorter (MACS) beads. Macrophage colony-stimulating
factor (M-CSF)-expanded osteoclast precursors were
treated with M-CSF and receptor activator of nuclear factor
κB-ligand (RANKL) for 5 days, in the presence or absence
of autologous ZOL-activated γδ T cells. In some wells osteo-
clast precursors were incubated with 10% (v/v) conditioned
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medium from 72 h cultures of PBMCs treated with ZOL, as
described above. To assess the contribution of interferon
(IFN)-γ to the inhibitory effect of γδ T cells (or conditioned
medium) on osteoclast formation, affinity-purified
polyclonal goat anti-human IFN-γ antibody (10 μg/ml) was
added to the cultures. Data shown are the mean ± standard
deviation from two experiments from independent donors.
Fig. S4. Activated γδ T cells and CD4+ T cells inhibit the
resorptive activity of mature osteoclasts. Mature osteoclasts
were seeded onto dentine discs and cultured with resting or
activated γδ T cells (a), or resting or activated CD4+ T cells
(b), for 6 days. The resorptive area was quantified using
reflected light microscopy and in-house software to deter-
mine resorption pits. Data shown are the mean ± standard
error of the mean from three experiments from independ-
ent donors. ***P < 0·001.
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